Press release
Key Influencer in the Cholangiocarcinoma Market 2025: Rising Liver Disease Incidence Drives The Growth Of The Market Driver
Cholangiocarcinoma Market
The increasing liver disease incidence is expected to propel the growth of the cholangiocarcinoma market going forward. Liver diseases, including conditions like hepatitis, cirrhosis, fatty liver disease, and liver cancer, impair the normal function of the liver. The rising incidence of liver diseases is driven by risk factors such as obesity, diabetes, alcohol consumption, and viral hepatitis infections. Chronic liver conditions, particularly inflammation and cirrhosis, increase the risk of cholangiocarcinoma, a type of cancer that affects the bile ducts, as they promote bile duct damage and malignant cell transformation. For example, in December 2024, the Office for Health Improvement and Disparities reported a 3.6% rise in premature deaths from alcoholic liver disease in 2023, underlining the growing impact of liver diseases. As liver disease prevalence rises, it will continue to fuel the growth of the cholangiocarcinoma market.
Get Your Cholangiocarcinoma Market Report Here:
https://www.thebusinessresearchcompany.com/report/cholangiocarcinoma-global-market-report
What is the projected compound annual growth rate (CAGR) of the cholangiocarcinoma market from 2025 to 2034, and what factors influence it?
The cholangiocarcinoma market has expanded rapidly, with projections showing an increase from $0.55 billion in 2024 to $0.63 billion in 2025, at a CAGR of 13.4%. The market's historical growth has been driven by the increasing incidence of liver and bile duct cancers, heightened awareness of rare cancers, a greater focus on personalized treatments, advancements in immunotherapy, and a growing geriatric population.
The cholangiocarcinoma market is forecasted to experience rapid expansion, reaching $1.02 billion by 2029 at a CAGR of 13.1%. Growth in this period is driven by the increasing adoption of precision medicine, rising healthcare expenditure, a growing focus on genetic testing, and an increased reliance on retail pharmacies. Key trends in the market include improvements in diagnostic techniques, the expansion of clinical trials, AI integration in diagnostics, innovations in drug delivery systems, an increase in clinical research, and advancements in drug development.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21139&type=smp
How are the latest trends influencing the growth of the cholangiocarcinoma market?
In the cholangiocarcinoma market, companies are developing targeted therapies to improve treatment outcomes for patients with biliary tract cancers. For example, in August 2023, Taiho Pharmaceutical Co. Ltd. launched LYTGOBI (futibatinib), an FGFR inhibitor designed to treat intrahepatic cholangiocarcinoma (iCCA) with FGFR2 gene fusions. The drug selectively inhibits the FGFR signaling pathway, slowing tumor growth and offering hope for patients who have progressed after chemotherapy.
What are the major segments of the cholangiocarcinoma market and their role in driving growth?
The cholangiocarcinoma market covered in this report is segmented -
1) By Cancer: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
2) By Product: Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin
3) By Therapy: Targeted Drug Therapy, Chemotherapy, Immunotherapy
4) By Route Of Administration: Oral, Subcutaneous, Intravenous
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-Commerce
Subsegments:
1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma, Mass-Forming Intrahepatic Cholangiocarcinoma
2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21139
Which regions are key players in the growth of the cholangiocarcinoma market?
North America was the largest region in the cholangiocarcinoma market in 2024. The regions covered in the cholangiocarcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the cholangiocarcinoma market?
Major companies operating in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., Taiho Pharmaceutical Co. Ltd.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21139&type=smp
What Is Covered In The Cholangiocarcinoma Global Market Report?
•Market Size Forecast: Examine the cholangiocarcinoma market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the cholangiocarcinoma market for a structured understanding.
•Key Players Overview: Analyze major players in the cholangiocarcinoma market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the cholangiocarcinoma market.
•Segment Contributions: Evaluate how different segments drive overall growth in the cholangiocarcinoma market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the cholangiocarcinoma market.
•Industry Challenges: Identify potential risks and obstacles affecting the cholangiocarcinoma market.
•Competitive Landscape: Review strategic developments in the cholangiocarcinoma market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Influencer in the Cholangiocarcinoma Market 2025: Rising Liver Disease Incidence Drives The Growth Of The Market Driver here
News-ID: 3935164 • Views: …
More Releases from The Business Research Company
Global Subcutaneous Immunoglobulin (SCIG) Market Projected to Grow at 12.7% CAGR …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Subcutaneous Immunoglobulin (SCIG) Industry Market Size Be by 2025?
The market for subcutaneous immunoglobulin (SCIG) has seen a swift expansion in the recent past. The market size is projected to escalate from $12.72 billion in 2024 to $14.39 billion in 2025, reflecting a compound annual growth…
2025-2034 Ranibizumab Market Roadmap: Insights for Competitive Advantage
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Ranibizumab Market Size By 2025?
The market for ranibizumab has experienced steady expansion in the past few years, with projections stating it will increase from $2.66 billion in 2024 to $2.76 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%. The growth…
Emerging Peptide And Oligonucleotide CDMO Market Trends: Strategic Partnerships …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Peptide And Oligonucleotide CDMO Market Size Growth Forecast: What to Expect by 2025?
In recent years, the peptide and oligonucleotide cdmo market has witnessed a swift escalation in its size. From $2.16 billion in 2024, it is projected to surge up to $2.42 billion in 2025 with a compound…
Oral Solid Dosage Pharmaceutical Formulation: Critical Driver Shaping the Chroni …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Oral Solid Dosage Pharmaceutical Formulation Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for oral solid dosage pharmaceutical formulations has seen robust growth in the last few years. Its size is expected to increase from $618.34 billion in 2024 to $653.26 billion in…
More Releases for Cholangiocarcinoma
Cholangiocarcinoma Market to Reach USD 2.87 Billion by 2034
The global cholangiocarcinoma market is positioned for steady growth, driven by increasing awareness, improved diagnostic capabilities, and the expanding approval of targeted drugs. Between 2024 and 2034, a combination of innovative drug pipelines, biomarker-based diagnostics, and supportive policy frameworks is expected to transform patient outcomes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70843
Market Overview
• Market Size (2024): USD 1.32 billion
• Forecasted Market Size (2034): USD 2.87 billion
• CAGR (2024-2034): ~8.1%
• Key Drivers: Genomic…
Cholangiocarcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2024" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cholangiocarcinoma Pipeline Report
• DelveInsight's Cholangiocarcinoma pipeline…
Cholangiocarcinoma Market Size was USD 786.1 million in 2021
The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032…
Global Cholangiocarcinoma Market
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Overview by Advance Technology, Future Outlook 2032
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Size was USD 786.1 Million in 2021
"The increase in Cholangiocarcinoma market size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline in the 7MM"
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma…
